A Phase 2 interventional study of Darbepoetin Alfa and Saline in PAIS, Neonatal Stroke and Perinatal Stroke, sponsored by UMC Utrecht. Completed at 1 site in Netherlands. Open to participants aged Up to 7 Days. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by UMC Utrecht · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 122 studies in Stroke with a site in Netherlands — 23 open to participants now, 31 under way, 5 of them phase 3. Stroke · Netherlands.
Among the 122 studies in Stroke with a site in Netherlands, this one is the 71st largest by enrollment of the 91 interventional ones that give a count, is one of 5 that started in 2017, is one of 7 in phase 2, and was the 66th registered.
8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.
Browse Stroke studies →23 of the 122 studies in Stroke with a site in Netherlands are open now. Recruiting first, the newest first:
Hospital Universitari Vall d'Hebron Research Institute · Sites in Netherlands, Belgium, Germany and 3 more countries
Ages 18+
Isala · Sites in Netherlands
Ages 18+
Leiden University Medical Center · Sites in Netherlands
Ages 18+
Maastricht University Medical Center · Sites in Netherlands
Ages 18+
Eli Lilly and Company · Sites in Netherlands, Argentina, Australia and 35 more countries
Ages 50+
A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →
Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.
This study: Up to 7 Days · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
122 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 9 · Phase 3 30 · Phase 4 9
First in 1998; this study’s year is marked. 5 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 80 is above the median of 48 across 6,049 interventional studies indexed under Stroke.
Median enrollment 640 across the 91 interventional studies, 432 across the 31 observational. Of the 77 that completed or were terminated, 24 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
45 of 122 have an industry lead sponsor. The 10 most frequent:
UMC Utrecht is the lead sponsor of 364 studies on the registry; 81 are open to participants now.
UMC Utrecht has 6 studies filed under Stroke — fewer than ten, so there is no comparison to draw.
5 of the studies in Stroke with a site in Netherlands that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06871969Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)Clinical Evaluation of EEG Device for the Triage of Stroke Patients in the Ambulance | 2026-12 |
| NCT06332989Leiden University Medical CenterStroke Triage Optimization by Ambulance Paramedics in the Pre-hospital Setting | 2027-02-01 |
| NCT04701684Philips Clinical & Medical Affairs GlobalWE-TRUST (Workflow Optimization to Reduce Time to Endovascular Reperfusion for Ultra-fast Stroke Treatment) | 2027-04-01 |
| NCT07702968Leiden University Medical CenterLow-Field MRI in Stroke Code Patients | 2027-04-01 |
| NCT04436978St. Antonius HospitalWhat is the Optimal Antithrombotic Strategy in Patients With Atrial Fibrillation Undergoing PCI? | 2027-10-01 |
Add all 5 to your calendar (.ics) → With an account.
Among the 122 studies in Stroke with a site in Netherlands, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of the study is to perform a randomized double-blind placebo controlled prospective study in newborn infants with MRI confirmed Middle Cerebral Artery (MCA) Perinatal Arterial Ischemic Stroke (PAIS) with darbepoetin. It will be investigated whether intravenous administered darbepoetin can induce the formation of neuronal tissue and restore brain function in neonates who suffered from PAIS compared to placebo treated controls. The ultimate goal of this study is therefore to develop a therapy using erythropoiesis-stimulating agents (ESA) such as darbepoetin to reduce or even prevent lifelong consequences of PAIS-related brain injury in this group of term newborns.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Darbepoetin alfa (Aranesp, Amgen)
Drug: Darbepoetin Alfa
Saline
Drug: Saline
Darbepoetin alfa (Aranesp, Amgen) 2 doses of 10 microgram/kg i.v.
Also known as: Aranesp
The placebo will consist of saline, containing 9.0 g of salt per liter (0.90%) i.v.
Also known as: Sodium Chloride
Change in stroke tissue loss
The primary objective is to determine whether there is a difference in the degree in stroke tissue loss between darbepoetin and placebo treatment, which will be measured by the change in lesion size between the time of onset of the insult and 6-8 weeks of age. The primary endpoint will be estimated using advanced volumetric magnetic resonance (MRI) techniques, performed within one week after clinical presentation and at 6-8 weeks of age.
Time frame: 6-8 weeks of age
Reorganization of corticospinal connectivity
To assess whether there are differences between darbepoetin and placebo treatment in Diffusion Tensor Imaging (DTI) parameters of selected regions of interest. DTI-MRI techniques are performed at 6-8 weeks of age.
Time frame: 6-8 weeks of age
Neurodevelopment
To assess cognitive and motor development at 18 months of age using the Bayley Scales of Infants and Toddler Development (BSITD)-III scores compare them between groups (darbepoetin vs placebo).
Time frame: 18 months of age
Neurological assessment
To assess neurological deficit and function using the Pediatric Stroke Outcome Measure (PSOM) and compare this score between groups (darbepoetin vs placebo). The PSOM is performed at 18 months of age.
Time frame: 18 months of age
Development of Cerebral Palsy
Development of Unilateral Spastic Cerebral Palsy (USCP) using the Gross Motor Function Classification system (GMFCS) and compare this between groups (darbepoetin vs placebo).
Time frame: 18 months of age
Plan to share: No
Ran from Jul 2017 to primary completion in Jun 2025, 95 months.
Of 112 non-industry phase 2 interventional studies under Stroke, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 60. This study's 95 months is above that.
Counting every sponsor, half of 132 studies reached it within 40 months; a quarter within 24 and three quarters within 59.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 17, 2026: primary completion Dec 2024 → Jun 2025 and completion Jun 2025 → Nov 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Darbepoetin alfa